Evidence map›Paper›PMID 32921403›Full record

ArticleAmerican journal of surgery2020

Enhanced recovery after surgery is safe for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Robert Cg Martin, Bryce M Marshall, Prejesh Philips, Michael Egger, Kelly M McMasters, Charles R Scoggins

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Incidence and outcomes of postoperative paralytic ileus after cytoreductive surgery with HIPEC: A population-based study.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Robert Cg MartinDepartment of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA. Electronic address: Robert.Martin@louisville.edu.
Bryce M MarshallDepartment of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA.
Prejesh PhilipsDepartment of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA.
Michael EggerDepartment of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA.
Kelly M McMastersDepartment of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA.
Charles R ScogginsDepartment of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, USA.
University of Louisville · US

Funding

University of Louisville Cancer Education ProgramR25CA134283 · NCI · UNIVERSITY OF LOUISVILLE · PI HEIN, DAVID W, KIDD, LA CREIS RENEE · 2011 to 2022
$3.1M
NCI NIH HHS R25 CA134283
6 · The paper itself

Abstract

introductionCytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an effective, aggressive approach to treating intraperitoneal carcinomatosis. This study aimed to test the efficacy/safety of an enhanced recovery (ERAS) program after CRS-HIPEC surgery.

methodsReview of an IRB-approved prospectively maintained HIPEC database from 2003 to 2019. Adverse events and outcomes related to the primary operation were noted.

results125 HIPEC procedures performed met inclusion criteria, with 20 treated through ERAS. There was an improvement in LOS (ERAS: 9, 6.0-28.0; non-ERAS: 11.0, 6.0-45.1, P = 0.5), a significant reduction in opioid use during hospitalization (ERAS Total Morphine Equivalents 156 vs Non-ERAS of 856, p < 0.001), and a significant reduction in discharge opioid requirements (ERAS 55% of patients, non-ERAS 97%, p < 0.02).

conclusionERAS for CRS-HIPEC is safe, while maintaining quality outcomes, and leads to significant reductions in hospital opioid use and discharge narcotic usage. Our experience supports the full implementation of an ERAS protocol for HIPEC.

Indexed as

Cytoreduction Surgical ProceduresEnhanced Recovery After SurgeryHyperthermic Intraperitoneal ChemotherapyAdultAgedAged, 80 and overAnalgesics, OpioidCarcinomaCombined Modality TherapyFemaleHumansMaleMiddle AgedPain ManagementPeritoneal NeoplasmsPostoperative PainAnalgesics, OpioidEnhanced recovery after surgeryERASHIPEC

Identifiers

PMID32921403
PMCPMC9514086
OpenAlexW3083341305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.